Press Releases

Press Releases

Samsung Biologics Reports Third Quarter 2023 Financial Results

COMPANY NEWS - Samsung Biologics Reports Third Quarter 2023 Financial Results

• Recorded Q3’23 consolidated revenue of KRW 1,034 billion 

• Recorded Q3’23 consolidated operating profit of KRW 319 billion 

• Achieved record-high quarterly consolidated revenue as a result of successful Plant 4 ramp-up bolstering order backlog


​Incheon, S. Korea, October 25, 2023 – Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2023. 

 

"We have achieved a remarkable milestone with consolidated sales surpassing KRW 1 trillion in a single quarter, ultimately demonstrating our commitment to excellence and innovation," said John Rim, CEO and President of Samsung Biologics. "Our expanding partnerships with global leading pharmaceutical companies and a thriving sales backlog reflect the trust our clients place in us and our capabilities. Looking ahead, our expansion plans, including the construction of the ADC facility and Plant 5, will meet the increasing market demand and support our clients’ needs for both capacity and business diversification."

 

THIRD QUARTER 2023 RESULTS

 

In the third quarter of 2023, consolidated revenue exceeded KRW 1 trillion for the first time in a single quarter, marking an 18% increase from the KRW 873 billion reported in the same period of the previous year. This is attributed to a rapid increase in the operating rate of Plant 4 and a robust sales backlog, resulting in a projected over 20% annual growth in consolidated revenue. Consolidated operating profit for the third quarter of 2023 reached KRW 319 billion, while net profit was KRW 240 billion with an EBITDA of KRW 457 billion.

 

On a standalone basis, the company reported KRW 883 billion in revenue for the third quarter of 2023, reflecting a 31% increase from KRW 675 billion in the same period in the previous year. Operating profit reached KRW 382 billion, marking a 23% increase from the prior year. 

 

The company also expanded its strategic partnerships to include 14 of the top 20 global pharmaceutical companies, further solidifying the company’s position as a trusted CDMO partner. As of October, Samsung Biologics has accumulated contracts worth over USD 11.8 billion, which includes the previously announced long-term partnership with Pfizer and an expanded strategic agreement with Bristol Myers Squibb.

 

[Consolidated Earnings, KRW billion] 

 

Q3’23

Q3’22

YoY Change

Revenues

1,034

873

+18.4%

Operating Profit

319

325

-1.9%

Net Profit

240

129

+86.0%

EBITDA

457

409

+11.6%

 

FISCAL YEAR 2023 OUTLOOK
 

Samsung Biologics is committed to meeting the growing demand for high-quality biologics. The company’s expansion plans are on track, with the new Plant 5 set to commence operations by April 2025, adding an 180KL of capacity.

 

As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest construction timeline at 24 months, made possible by the company’s standardized design, accumulated operational excellence, and proven expertise.

 

To expand its business portfolio, Samsung Biologics’ separate antibody-drug conjugate (ADC) manufacturing facility is expected to be cGMP-ready within 2024 in order to develop and explore innovative technologies for next-generation biomedicines.

 

This aligns with the company’s strategic investments, made through the Samsung Life Science Fund, to support biotechs like AimedBio and Araris Biotech AG who are pioneering ADC technology.

 

Samsung Biologics also continues to engage and drive action in the sustainability front. In July, together with global leaders from across the healthcare sector under The Sustainable Markets Initiative Health Systems Task Force, Samsung Biologics President and CEO John Rim announced an open letter, calling on suppliers to commit to joint, minimum climate and sustainability targets.

 

The company has also joined the Sustainable Aviation Buyers Alliance (SABA), a non-profit organization accelerating the path to net-zero aviation, to help reduce emissions by investing in high-integrity Sustainable Aviation Fuel (SAF).
 

For more details on performance and financials, please refer to the Earnings Release.

COMPANY NEWS - Samsung Biologics Reports Third Quarter 2023 Financial Results


• Recorded Q3’23 consolidated revenue of KRW 1,034 billion 

• Recorded Q3’23 consolidated operating profit of KRW 319 billion 

• Achieved record-high quarterly consolidated revenue as a result of successful Plant 4 ramp-up bolstering order backlog


​Incheon, S. Korea, October 25, 2023 – Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2023. 

 

"We have achieved a remarkable milestone with consolidated sales surpassing KRW 1 trillion in a single quarter, ultimately demonstrating our commitment to excellence and innovation," said 15.6933px; font-size: 11pt; font-family: " 맑은="" 고딕";="" text-align:="" center;"="">+11.6%

 

FISCAL YEAR 2023 OUTLOOK
 

Samsung Biologics is committed to meeting the growing demand for high-quality biologics. The company’s expansion plans are on track, with the new Plant 5 set to commence operations by April 2025, adding an 180KL of capacity.

 

As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest construction timeline at 24 months, made possible by the company’s standardized design, accumulated operational excellence, and proven expertise.

 

To expand its business portfolio, Samsung Biologics’ separate antibody-drug conjugate (ADC) manufacturing facility is expected to be cGMP-ready within 2024 in order to develop and explore innovative technologies for next-generation biomedicines.

 

This aligns with the company’s strategic investments, made through the Samsung Life Science Fund, to support biotechs like AimedBio and Araris Biotech AG who are pioneering ADC technology.

 

Samsung Biologics also continues to engage and drive action in the sustainability front. In July, together with global leaders from across the healthcare sector under The Sustainable Markets Initiative Health Systems Task Force, Samsung Biologics President and CEO John Rim announced an open letter, calling on suppliers to commit to joint, minimum climate and sustainability targets.

 

The company has also joined the Sustainable Aviation Buyers Alliance (SABA), a non-profit organization accelerating the path to net-zero aviation, to help reduce emissions by investing in high-integrity Sustainable Aviation Fuel (SAF).
 

For more details on performance and financials, please refer to the Earnings Release

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION